Folgen
-
We wrap up season 1 back where we started, with Dr BJ Miller, one of the world's leading voices in palliative care. The connection between psychedelics and his field is a strong one, with a lot of the current research focused on easing suffering at the end of life. Amongst other things, BJ and Will talk about how they think about their own deaths, their visions for the future of their profession, the need for more humanity in medicine and where spirituality fits, and BJ's new online palliative care counselling service, Mettle Health.
That's it from us this season - thanks for listening, and be sure to subscribe via your favourite podcast platform for updates on what's next. -
While we count down to the end of the year and the end of Season One, we thought it was timely to take stock of the emerging field of psychedelic medicine in New Zealand.
In this episode, Will covers off the country's first psychedelic medicine conference, the momentum that's building in the research community, what's happening with the only psychedelic that's legal here for therapy - ketamine - and what lies ahead.
Be sure to tune in next week as we wrap up the season the way we started it, with a conversation with BJ Millar. And don't forget to subscribe via Apple Podcasts, Spotify or your favourite platform so you don't miss the start of Season Two. -
Fehlende Folgen?
-
Psychologist Dr Rosalind Watts is best known for her work at Imperial College London where she has done pioneering work in using psilocybin for depression.
More recently, she became Clinical Director at Synthesis Retreats, an organisation that offers medically supervised psychedelic retreats in Amsterdam.
Having had experience working with psychedelics in both research and commercial settings, Ros brings a unique perspective to the conversation.
Amongst other things In this episode, we explore some of the challenges of bringing these medicines into the marketplace, explore the treatment models Ros has developed, discuss the dearth of diversity in the field, and get a reality check around the hype surrounding psychedelics.
Ros has some thought provoking things to say about the need for clinicians to their keep egos in check when working with these medicines, too. -
Dr Marg Ross is a senior psychologist working in Palliative Care at St Vincent’s Hospital, Melbourne, and the clinical lead in Australia’s first ever psychedelic medicine trial, which is looking at psilocybin and psychotherapy for end of life depression and anxiety.
Marg had watched what was going on in the Northern Hemisphere with interest and waited for somebody to get a study off the ground in Australia before deciding nothing was going to happen in a hurry - so she’d better do it herself. It took a year to get approval from ethics committees, federal and state authorities, and then the study faced further delays when COVID hit.
We talked with Marg about the challenges of getting approval for psychedelic research and the very real stigma and risk researchers can face, the sense of privilege she has felt working with the few patients who were treated in her trial before COVID intervened, what psychedelic therapy might look like in mainstream clinical use and why palliative care is such a magnet for this kind of work.
Marg was so much fun to interview, despite the seriousness of the topic at hand - and we loved having both an Australasian and female voice to add to the mix.
-
Dr Steven Mandel and his son, Sam, run Ketamine Clinics of Los Angeles - one of the first infusion clinics in the United States.
At KCLA they do ketamine infusions all day, every day, and they have developed their own regimen of personalised dosing that takes patients to optimal 'altitude' to change their minds, as well as their brains.
The Mandels are firm believers in the value of stand alone ketamine infusions, even without psychotherapy, and say they've seen near-miraculous and lasting transformations over the course of more than 10,000 infusions.
We talked with them about their model and protocols, what they've learned over the past six years, why ketamine isn't the 'get rich quick' business some think it is, and how they believe the drug catalyses change that can be lasting - despite its short-acting nature. -
Professor David Nutt is the Chair of Neuropsychopharmacology at Imperial College London and a world-leading psychedelic researcher. He's a strong advocate for a rational, evidence based approach to psychedelics, and continues to, in his own words, 'call out the lies' about them, wherever he can.
his latest study, looking into MDMA and alcoholismhis theory about why psychedelics appear to be especially effective in treating 'internalising disorders' like depression, anxiety and OCDthe nature of consciousness and where psychedelics fitthe risk that the high price tag for psychedelic assisted psychotherapy could leave it out of reach for most people and the role community healing could play
David is currently Chair of DrugScience and President of the European Brain Council, has edited the Journal of Psychopharmacology for over two decades and acts as the psychiatry drugs advisor to the British National Formulary. He is also the host of the very popular
The Drug Science Podcast.
We covered a lot of ground with David, including: -
Saj Razvi has been involved in psychedelic therapy from almost every angle - as a researcher in the MAPS MDMA trials, as a psychotherapist, and now as a trainer of others looking to incorporate psychedelics into their practice.
Saj believes that psychedelics don't necessarily fit with traditional therapy, and so has created a modality designed specifically for work with them.
He's a passionate advocate for these medicines, but also knows from first hand experience that things can go horribly wrong. Saj continues to tell the story of what happens as a cautionary tale for others.
We talked with Saj about why he believes therapy should start with the body, the extraordinary results he's seen from people working with these substances, the enormous time commitment MDMA therapy demands, both in and out of session and his advice for therapists just getting started in the field.
-
Dr Geoff Noller is a medical anthropologist specialising in psychotropic drug research, with an emphasis on drug use as a cultural practice.
We talked with Geoff about his work looking at kiwi attitudes to cannabis use, the nature of consciousness and reality, fears and prejudices around mind altering states and substances, and his experiences as principal investigator on an ibogaine study for opioid dependence. Our interview took place on the morning of the cannabis referendum decision – and as a side note, he was keen for us to share this link to help explain some of the attitudes that endure when it comes to cannabis and all mind-changing substances. -
Rick Doblin decided he wanted to be a psychedelic therapist when he was in his late teens, and has since dedicated his life to building the foundations needed to enable him - and others - to do the work legally, safely and effectively.
He founded the Multidisciplinary Association for Psychedelic Studies (MAPS) in 1986, a research and advocacy organisation that has spent decades researching the use of psychedelics and cannabis as medicines. MAPS is now closer than anyone has ever been to bringing MDMA therapy into the mainstream, with phase three trials underway into using MDMA for PTSD, and the achievement of 'breakthrough status' for this therapy with the US Federal Drug Administration.
We talked with Rick about how long he thinks it will be before psychedelic therapy is approved for widespread use, the importance of specific training for Kiwi clinicians just starting out in the field, how just taking another substance isn't always the answer, and why the medicine alone, isn't enough. -
Psychedelic medicines have a long and chequered history - not the least because of wariness from the medical mainstream. That perception is changing fast, though, with a growing number of respected international researchers and clinicians pointing to the evidence of their potential to provide safer, faster and more effective treatments for mental illness and existential distress.
There's a cultural shift going on, too, with support coming from unexpected quarters, including that of well-known writer, journalism lecturer and activist Michael Pollan, who brought the science to life by taking readers on his own personal psychedelic adventures in the 2018 book, How To Change Your Mind.
This week's guest, the University of Auckland's Dr Lisa Reynolds, says Pollan’s book was one of the influences that sparked her research interest in the potential benefits of psychedelic medicine for end of life anxiety and depression. Lisa is also involved in some vital qualitative research to measure attitudes toward psychedelics as medicines of not only patients, but the clinicians treating them, too. -
Our chat with Dr Suresh Muthukumaraswamy took us down the kind of rabbit-hole that's becoming all too familiar as we continue our exploration of psychedelics as medicine. Despite - or because of - all the twists and turns it was an invigorating and thought provoking conversation, even if we did just scratch the surface of some of the perplexities and complexities of working with these medicines.
Suresh is a neuroscientist and associate professor in the School of Pharmacy at the University of Auckland, has done groundbreaking research on psilocybin, LSD and ketamine here and at Imperial College London, and along with Will and others, is about to start one of the world's first LSD microdosing trials. -
A special bonus episode this week - with only a matter of days until the polls close, we thought we'd better get this one out pronto.
West Auckland GP, Dr Graham Gulbransen, is a pioneer in the emerging field of medicinal cannabis. We had a great chat with him about the referendum, the reluctance of GPs to prescribe cannabis-based products and how the future could look if it's a 'yes' next Saturday.
For the ethnobotanically curious, there's a mention of Will's brand new mineral water product - learn more at http://www.senza.nz
More about Graham's practice https://www.cannabiscare.nz -
Dr BJ Miller is best known for his Ted Talk, What Really Matters At The End Of Life https://tinyurl.com/y3tn7wfr.
BJ is not a psychedelic medicine practitioner, but has a lot to say about altered states and their role in palliative care, end of life choices, and what's going on in California as more psychedelics are decriminalised for medicinal and recreational use.
We talk with BJ about these things and more, including how he came to terms with the accident that cost him his legs and an arm at the age of 19, how it changed his perspective on both living and dying, and psychedelic experiences without the drugs.
